Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01567436
Other study ID # 10728
Secondary ID
Status Completed
Phase Phase 4
First received February 28, 2012
Last updated September 26, 2012
Start date February 2012
Est. completion date August 2012

Study information

Verified date September 2012
Source FHI 360
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review BoardKenya: Institutional Review BoardKenya: Pharmacy and Poisons BoardZambia:Institutional Review Board (UNZA REC)Zambia: Pharmaceutical Regulatory Authority
Study type Interventional

Clinical Trial Summary

Male Circumcision (MC) is the only new biomedical method to demonstrate consistent efficacy as an HIV prevention intervention in randomized controlled trials (WHO and UNAIDS, 2007), based on three randomized controlled trials in Kenya, Uganda, and South Africa, that reported a protective effect of about 60%


Description:

The World Health Organization, the Joint United Nations Programme on HIV/AIDS (UNAIDS), and other global reproductive health organizations have recognized the highly protective effect of male circumcision to prevent HIV infection in men. Male Circumcision (MC) is the only new biomedical method to demonstrate consistent efficacy as an HIV prevention intervention in randomized controlled trials, based on three randomized controlled trials in Kenya, Uganda, and South Africa, that reported a protective effect of about 60%. Subsequent studies have confirmed the value and persistence of MC's protection against HIV infection, and have demonstrated that MC also reduces the transmission of human papillomavirus.

A wide variety of instruments, devices, and techniques are used around the world for male circumcision. The WHO, UNAIDS and JHPIEGO document entitled Manual for Male Circumcision under Local Anesthesia, includes step-by-step instructions for performing adult male circumcision using three different surgical procedures: the forceps-guided, dorsal slit, and sleeve resection methods. Procedure times for these techniques are approximately 20-30 minutes excluding anesthesia and involve control of unavoidable bleeding and a significant amount of suturing, and can be associated with complications that include hematoma formation, infection, unsatisfactory cosmetic result, lacerations of the penile or scrotal skin and injury to the glans, particularly among inexperienced surgeons. Although training is necessary regardless of method, devices for MC have the potential to reduce both training time and surgical duration because neither hemostasis nor suturing is needed for most devices.

The Shang Ring is an innovative device for adult male circumcision that has been on the Chinese market since 2005. The Shang Ring is manufactured by Wuhu SNNDA Medical Treatment Appliance Technology Co., Ltd (SNNDA).

In the current African setting, only surgical circumcision is available for adults. Devices such as the Shang Ring have the potential to simplify and shorten surgery by eliminating the need for suturing and hemostasis. Data from two small studies in Kenya suggest that the Shang Ring has an acceptable safety profile. A randomized controlled trial was conducted in Kenya and Zambia to provide further data.

Circumcision using the Shang Ring involves a few simple steps. First, a special measuring strip is used to determine which Shang Ring size to use. Following administration of local anesthesia, the inner ring is fitted at the base of the glans penis. Next, the foreskin is everted over the inner ring and the outer ring is secured (locked) over the inner ring, thus encasing the foreskin. The sterile device forms a tight seal. The foreskin is excised and several nicks are made in the foreskin on the underside of the device to prevent formation of a stiff, circumferential scab. Bleeding is minimal and no suturing or hemostasis is required. Finally, the participant returns in seven days for removal of the Shang Ring device. After removal, a bandage is applied to the wound. Men may be given a supply of bandages and told to change the bandaging daily or as needed.


Recruitment information / eligibility

Status Completed
Enrollment 1200
Est. completion date August 2012
Est. primary completion date July 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 54 Years
Eligibility Inclusion Criteria:

All men enrolled in this research study must meet the following inclusion criteria:

- Must be aged 18 and 54 years;

- Must be uncircumcised (on examination);

- Must be in good general health;

- Must agree to HIV counseling and testing no more than one week before the procedure;

- Must be free of genital ulcerations or other visible signs of STI (on examination);

- Must be able to understand study procedures and requirements of study participation;

- Must agree to return to the healthcare facility for the full schedule of follow-up visits after his circumcision;

- Must freely consent to participate in the study and sign a written informed consent form;

- Must have a cell phone or access to a cell phone; and,

- Must agree to provide the study staff with an address, phone number, or other locator information while participating in the research study.

Exclusion Criteria:

- A man will be excluded from participation in this research study if he has any of the following exclusion criteria:

- Has a known allergy or sensitivity to lidocaine or other local anesthesia;

- Takes a medication that would be a contraindication for elective surgery, such as an anticoagulant or steroid;

- Has known bleeding/clotting disorder (e.g. hemophilia); or

- Has an active genital infection, anatomic abnormality or other condition (e.g. severe obesity, diabetes or sickle cell anemia), which in the opinion of the surgeon, prevents the man from undergoing a circumcision as part of this study;

- Is currently participating in another biomedical study.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Device:
Shang Ring
The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. To ensure that men cannot remove the device prematurely, the locking mechanism must be broken open using a tool that is similar to a scalpel handle. Then, a pair of scissors is used to remove the inner ring, and a bandage or gauze dressing is applied.

Locations

Country Name City State
Kenya Homa Bay District Hospital male circumcision clinic Homa Bay Nyanza
Zambia Society for Family Planning Clinic Lusaka

Sponsors (7)

Lead Sponsor Collaborator
FHI 360 Bill and Melinda Gates Foundation, EngenderHealth, Kenya National AIDS & STI Control Programme, Ministry of Medical Services, Kenya, University Teaching Hospital, Lusaka, Zambia, Weill Medical College of Cornell University

Countries where clinical trial is conducted

Kenya,  Zambia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants with Adverse Events as a Measure of Safety and Tolerability 42 days Yes
Secondary Acceptability of the Shang Ring Procedure 42 days No
Secondary Percentage of men completely healed at 42 days 42 Days Yes
See also
  Status Clinical Trial Phase
Completed NCT01247844 - Evaluation of Healing at Three Time Intervals and Potential for Spontaneous Detachment N/A
Completed NCT02242565 - Safety and Effectiveness of Different ShangRing Device Sizes for Adult Male Circumcision in Lusaka, Zambia N/A
Completed NCT00993811 - The Shang Ring: A Novel Male Circumcision Device for HIV Prevention Phase 1
Completed NCT02281435 - Follow Up Study to Evaluate a Non-Surgical Device for Adult Male Circumcision for Screen Failure Subjects N/A
Completed NCT04263064 - High Volume Caudal Study Early Phase 1
Completed NCT02091726 - Phase 4 Field Trial of the Unicirc Instrument With Tissue Adhesive N/A
Completed NCT02309710 - Male Circumcision (MC) Using the ShangRing™ Device in Malawi Phase 1
Completed NCT02167776 - From Obstacles to Opportunities for Male Circumcision in Tanzania N/A
Completed NCT01150370 - A Pivotal Study to Assess the Safety and Efficacy of The PrePex System, a Male Circumcision Device and Methodology for Rapid Scale up of Painless and Bloodless National Circumcision Programs, in Urban and Remote Rural Settings N/A
Completed NCT01434628 - Cohort Field Study to Assess the Safety and Efficacy of the PrePex Device for Non-Surgical Circumcision When Performed by Nurses N/A
Active, not recruiting NCT03914365 - Pudendal Nerve Block vs Penile Nerve Block for Analgesia During Pediatric Circumcision N/A
Completed NCT01921608 - Safety Study of the PrePex Device for Non-Surgical Adult Male Circumcision During Phased in National Implementation in an Effort to Prevent the Spread of HIV N/A
Completed NCT03634358 - Bipolar Scissors for Circumcision N/A
Completed NCT02277795 - Evaluation of the AccuCirc for Early Infant Male Circumcision in Nyanza, Kenya N/A
Completed NCT03223532 - Randomized Trial Comparing PrePex Day 7 Foreskin Removal Procedure (FRP) to a Day 0 PrePex FRP . N/A